Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 11/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 11/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27580966 | 1.00 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKSMYD3ALDH1A1 | |
| SCHEMBL6074806 | 0.91 | TAS1R3 (0.57) | TAS1R3TAS1R1CTSK | |
| SCHEMBL6075180 | 0.89 | SMYD3 (0.41) | TAS1R3TAS1R1CTSKSMYD3ALDH1A1 | |
| SCHEMBL6074471 | 0.85 | L3MBTL1 (0.50) | ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL6986486 | 0.84 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKSMYD3ALDH1A1 | |
| SCHEMBL6074325 | 0.84 | LMNA (0.52) | TAS1R3TAS1R1CTSKSMYD3ALDH1A1 | |
| SCHEMBL7135292 | 0.83 | CTSK (0.47) | TAS1R3TAS1R1CTSKSMYD3 | |
| SCHEMBL7136463 | 0.83 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSKSMYD3ALDH1A1 | |
| SCHEMBL6799810 | 0.81 | MEN1 (0.49) | ALDH1A1MAPTKMT2A | |
| SCHEMBL25496208 | 0.79 | TAS1R3 (0.61) | TAS1R3TAS1R1CTSKMAPTPPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| CN-1455771-A | Cyclic amine phenyl Beta-3 adrenergic receptor agonists | WYETH LTD (US) | 2003-11-12 | — | — | CN | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | TAS1R3 135/4885TAS1R1 175/4885CTSK 4147/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | TAS1R3 135/4885TAS1R1 175/4885CTSK 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.